Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.
A young woman with primary pulmonary hypertension presented with interstitial lung disease approximately 5 years after successful treatment with IV prostacyclin. The pathology was consistent with nonspecific interstitial pneumonitis and was unresponsive to steroids and immunosuppressive medications. We speculate that further cases of this syndrome may be reported as more patients are living beyond 5 years with prostacyclin.
Kesten
S
S
Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. skesten@rush.edu
Dainauskas
J
J
McLaughlin
V
V
Rich
S
S
D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D011464:Epoprostenol / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008168:Lung / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D013577:Syndrome; D013997:Time Factors
D000959:Antihypertensive Agents; D011464:Epoprostenol